• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by HTG Molecular Diagnostics Inc. (Amendment)

    12/2/22 4:30:38 PM ET
    $HTGM
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HTGM alert in real time by email
    SC 13D/A 1 f121223sc13da1.htm AMENDMENT NO. 1

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 1)1

     

    HTG Molecular Diagnostics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    40434H203

    (CUSIP Number)

     

    Milton C, Ault, III

    BITNILE Holdings, Inc.

    11411 Southern Highlands Parkway, Suite 240

    Las Vegas, NV 89141

    (949) 444-5464

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 30, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    _______________

    1            The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     - 1 - 

    CUSIP No. 40434H203

     

    1

    NAME OF REPORTING PERSONS

     

    BitNile Holdings, Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    800,000(1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    800,000(1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    800,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.24%

    14

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)

    Represents shares of Common Stock held by Ault Lending LLC (formerly, Digital Power Lending, LLC).

     

     - 2 - 

    CUSIP No. 40434H203

     

    1

    NAME OF REPORTING PERSONS

     

    Ault Lending, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    CALIFORNIA

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    800,000

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    800,000

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    800,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.24%

    14

    TYPE OF REPORTING PERSON

     

    OO

     

     - 3 - 

    CUSIP No. 40434H203

     

    1

    NAME OF REPORTING PERSONS

     

    Milton C. Ault, III

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A.

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    800,000(1)

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    800,000(1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    800,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.24%

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Represents shares of Common Stock held by Ault Lending, LLC.

     

     - 4 - 

    CUSIP No. 40434H203

     

    The following constitutes Amendment No. 1 (“Amendment No. 1”) to the Schedule 13D filed by the undersigned on August 5, 2022 (the “Schedule 13D”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. Except as otherwise specified in this Amendment No. 1, all items in the Schedule 13D are unchanged. All capitalized terms used in this Amendment No. 1 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D.

     

    Item 2.Identity and Background.

     

    Item 2 of the Schedule 13D is hereby amended as follows:

     

    All references to “Digital Power Lending, LLC” are hereby replaced with “Ault Lending, LLC”, which entity changed its name subsequent to the Schedule 13D.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    The Shares purchased by Ault Lending, LLC were purchased with working capital in open market purchases. The Shares transacted by Ault Lending, LLC as reported on this Amendment No. 1 decreased Ault Lending, LLC’s aggregate expenditures by $110,653.42. Consequently, as of the date of this Amendment No. 1, Ault Lending, LLC has expended an aggregate of $1,173,875.75 for the purchase of the Shares.

     

    Item 5.Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    The aggregate percentage of Shares reported owned by each Reporting Person herein is based upon 11,049,948 Shares outstanding, which is the total number of Shares outstanding as of November 3, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.

     

    A.BitNile Holdings, Inc.

     

    (a) As of the date hereof, BitNile Holdings, Inc. may be deemed to beneficially own 800,000 Shares, consisting of Shares held by Ault Lending, LLC. BitNile Holdings, Inc. may be deemed to beneficially own the Shares beneficially owned by Ault Lending, LLC by virtue of its relationship with such entity described in Item 2.

     

    Percentage: 7.24%

    (b)1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 800,000

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 800,000

     

    (c)BitNile Holdings, Inc. has not entered into any transactions in the Shares during the past sixty days.

     

    B. Ault Lending, LLC

     

    (a) As of the date hereof, Ault Lending, LLC beneficially owns 800,000 Shares held directly by it.

     

    Percentage: 7.24%

     

    (b)1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 800,000

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 800,000

     

     - 5 - 

    CUSIP No. 40434H203

     

    (c) Other than as previously disclosed on the Schedule 13D and the transactions set forth in Schedule A attached hereto, which are both incorporated by reference, Ault Lending, LLC has not entered into any transactions in the Shares during the past sixty days. All of such transactions were effected in the open market.

     

    C.Milton C. Ault, III

     

    (a) As of the date hereof, Mr. Ault may be deemed to beneficially own 800,000 Shares, consisting of Shares held by Ault Lending, LLC. Mr. Ault may be deemed to beneficially own the Shares beneficially owned by Ault Lending, LLC by virtue of his relationship with such entity described in Item 2.

     

    Percentage: 7.24%

     

    (b)1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 800,000

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 800,000

     

    (c)Mr. Ault has not entered into any transactions in the Shares during the past sixty days.

     

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    (d)No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

     

    (e)Not applicable.

     

     - 6 - 

    CUSIP No. 40434H203

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated:    December 2, 2022

     

     

        BITNILE HOLDINGS, INC.

    /s/ Milton C. Ault, III

         
    MILTON C. AULT, III   By:

    /s/ Milton C. Ault, III

          Name: Milton C. Ault, III
          Title: Executive Chairman

     

     

        AULT LENDING, LLC
           
        By:

    /s/ David J. Katzoff

          Name: David J. Katzoff
          Title: Manager

     

     - 7 - 

    CUSIP No. 40434H203

     

    SCHEDULE A

     

    Transactions in the Shares of Common Stock During the Last Sixty Days

     

    Ault Lending, LLC

     

    Nature of the Transaction Shares of Common Stock
    Purchased / (Sold)
    Price Per Share ($) Date of
    Transaction
    Sale of Common Stock (58,000) 0.4587 11/28/2022
    Sale of Common Stock (46,000) 0.3524 11/29/2022
    Sale of Common Stock (56,000) 0.3889 11/30/2022
    Sale of Common Stock (140,000) 0.3290 12/01/2022

     

     

     

     

     

     

    Get the next $HTGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HTGM

    DatePrice TargetRatingAnalyst
    1/7/2022$5.00 → $8.00Hold → Buy
    Craig-Hallum
    More analyst ratings

    $HTGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HTG Molecular Diagnostics upgraded by Craig-Hallum with a new price target

      Craig-Hallum upgraded HTG Molecular Diagnostics from Hold to Buy and set a new price target of $8.00 from $5.00 previously

      1/7/22 10:15:02 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on HTG Molecular Diagnostics with a new price target

      SVB Leerink reiterated coverage of HTG Molecular Diagnostics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously

      5/14/21 6:42:26 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HC Wainwright & Co. reiterated coverage on HTG Molecular Diagnostics with a new price target

      HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $9.00 from $11.00 previously

      5/14/21 6:28:53 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Barat Stephen

      4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      6/9/23 8:11:23 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Barat Stephen

      4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      4/7/23 4:16:01 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3: New insider Barat Stephen claimed ownership of 1,361 shares

      3 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      2/10/23 4:34:09 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

      TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat

      5/18/23 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Highlights the Advantages of Its Drug Discovery Engine

      TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva

      5/16/23 8:47:40 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

      TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can

      5/10/23 5:51:27 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    SEC Filings

    See more
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      6/8/23 4:51:32 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      6/5/23 3:42:54 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      5/24/23 5:01:07 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Financials

    Live finance-specific insights

    See more
    • HTG Announces Certain Preliminary 2022 Unaudited Financial Results

      Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash

      1/6/23 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Reports Second Quarter 2022 Results

      TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled "Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research" fe

      8/11/22 4:05:00 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

      TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, August 11Time:4:30pm ETToll Free:1-800-954-0602 International:1-212-231-2936 Conference ID:2

      8/4/22 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

      SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/13/23 3:33:23 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

      SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/10/23 9:03:52 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by HTG Molecular Diagnostics Inc.

      SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/3/23 4:02:18 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials